# US 2013/0210661 A1 · Markers of vulnerability of the atherosclerosis plaque

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0210661 A1
- Document ID: US20130210661A1
- Status: Published application
- Kind: A1
- Application number: 13/808,516
- Filed: 2011-07-06
- Published: 2013-08-15
- Earliest claimed: 2010-07-06
- Inventors: Jeannette Fareh; Eric Malaud
- Web page: https://patentgrep.com/patent/US20130210661A1

## CPC

- G01N 33/6893: {related to diseases not provided for elsewhere}
- G01N 33/6866: {Interferon}
- G01N 33/6869: {Interleukin}
- G01N 2800/32: Cardiovascular disorders
- G01N 2800/323: Arteriosclerosis, Stenosis
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N 2800/60: Complex ways of combining multiple protein biomarkers for diagnosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates to methods for determining the presence of an unstable atherosclerotic plaque in an individual, comprising the steps of measuring the presence and/or level of at least one biochemical marker in a biological sample obtained from said individual, and, based on the result of this measurement, determining the presence of an unstable atherosclerotic plaque in the individual. The present invention also relates to a method for diagnosing a vascular or metabolic disease or an increased predisposition to an adverse outcome in an individual comprising determining the presence of an unstable atherosclerotic plaque in the individual. The present invention also relates to an in vitro method for identifying markers of the presence of an unstable atherosclerotic plaque in a subject, using depleted protein extracts obtained from proteins extracts from biological samples representative of stable and unstable atherosclerotic plaques.

## Claims

### Claim 1

A method for determining the presence of an unstable atherosclerotic plaque in an individual, comprising the steps of:
a1) measuring the presence and/or level of at least one biochemical marker in a biological sample obtained from said individual, said biochemical marker being selected from the group consisting of:
calponin-1,
alpha B crystallin,
phosphatidylethanolamine-binding protein 1,
aciculin,
mature cathepsin K,
osteoglycin,
peroxiredoxin-2,
dihydropyrimidinase-like 3,
serum amyloid P component,
serpin B9,
serpin B9—granzyme B complex,
pro-cathepsin D,
thrombospondin-2,
thrombospondin-1,
pro-collagen C-endopeptidase enhancer-1,
DJ-1 oncogene,
tissue inhibitor of metalloproteinase 1,
microfibril-associated protein-4,
heat shock protein 27,
IL-12,
vascular endothelial growth factor,
IL-8,
IL-1ra,
granulocyte colony-stimulating factor,
growth-regulated alpha protein,
IL-13,
leukemia inhibitory factor,
IL-1 alpha,
IL-1 beta,
interferon alpha-2, and
stromal cell derived factor 1 alpha;
b1) based on the result of the measurement in step a1), determining the presence of an unstable atherosclerotic plaque in the individual.

### Claim 2 (depends on 1)

The method according to claim 1, wherein step a1) comprises measuring the presence and/or level of (i) calponin-1 and (ii) at least one biochemical marker in a biological sample obtained from said individual, said biochemical marker being selected from the group consisting of:
alpha B crystallin,
phosphatidylethanolamine-binding protein 1,
aciculin,
mature cathepsin K,
osteoglycin,
peroxiredoxin-2,
dihydropyrimidinase-like 3,
serum amyloid P component,
serpin B9,
serpin B9—granzyme B complex,
pro-cathepsin D,
thrombospondin-2,
thrombospondin-1,
pro-collagen C-endopeptidase enhancer-1,
DJ-1 oncogene,
tissue inhibitor of metalloproteinase 1,
microfibril-associated protein-4,
heat shock protein 27,
IL-12,
vascular endothelial growth factor,
IL-8,
IL-1 ra,
granulocyte colony-stimulating factor,
growth-regulated alpha protein,
IL-13,
leukemia inhibitory factor,
IL-1 alpha,
IL-1 beta,
interferon alpha-2, and
stromal cell derived factor 1 alpha.

### Claim 3 (depends on 2)

The method according to claim 2, wherein step a1) comprises measuring the presence and/or level of
(i) calponin-1,
(ii) a second biochemical marker selected from the group consisting of:
alpha B crystallin,
phosphatidylethanolamine-binding protein 1,
aciculin,
mature cathepsin K,
osteoglycin,
peroxiredoxin-2,
dihydropyrimidinase-like 3,
serum amyloid P component,
serpin B9,
serpin B9—granzyme B complex,
pro-cathepsin D,
thrombospondin-2,
thrombospondin-1,
pro-collagen C-endopeptidase enhancer-1,
DJ-1 oncogene,
tissue inhibitor of metalloproteinase 1,
microfibril-associated protein-4,
heat shock protein 27,
IL-12,
vascular endothelial growth factor,
IL-8,
IL-1 ra,
granulocyte colony-stimulating factor,
growth-regulated alpha protein,
IL-13,
leukemia inhibitory factor,
IL-1 alpha,
IL-1 beta,
interferon alpha-2, and
stromal cell derived factor 1 alpha; and
(iii) at least one other biochemical marker selected from the group consisting of:
alpha B crystallin,
phosphatidylethanolamine-binding protein 1,
aciculin,
mature cathepsin K,
osteoglycin,
peroxiredoxin-2,
dihydropyrimidinase-like 3,
serum amyloid P component,
serpin B9,
serpin B9—granzyme B complex,
pro-cathepsin D,
thrombospondin-2,
thrombospondin-1,
pro-collagen C-endopeptidase enhancer-1,
DJ-1 oncogene,
tissue inhibitor of metalloproteinase 1,
microfibril-associated protein-4,
heat shock protein 27,
IL-12,
vascular endothelial growth factor,
IL-8,
IL-1 ra,
granulocyte colony-stimulating factor,
growth-regulated alpha protein,
IL-13,
leukemia inhibitory factor,
IL-1 alpha,
IL-1 beta,
interferon alpha-2, and
stromal cell derived factor 1 alpha;
said at least one other biochemical marker (iii) being different from said second biochemical marker (ii).

### Claim 4 (depends on 1)

The method according to claim 1, wherein step a1) is followed by a step a2) of comparing the presence and/or level of the at least one biochemical marker with at least one predetermined value, and wherein step b1) consists in determining the presence of an unstable atherosclerotic plaque in the individual, based on the comparison in step a2).

### Claim 5 (depends on 4)

The method according to claim 4, wherein the at least one predetermined value is the mean level of the at least one biochemical marker in a population of individuals known to have no unstable atherosclerotic plaque.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the biological sample is a liquid biological sample

### Claim 7 (depends on 6)

The method according to claim 6, wherein the liquid biological sample is selected from the group consisting of blood sample, serum, plasma and urine.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the biological sample is a tissue sample, preferably an artery sample.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the step of measuring the presence and/or the level of the at least one biochemical marker is carried out by immunological assay (simplex or multiplex), mass spectrometry, Multiple Reaction Monitoring (MRM), Stable Isotope Standards and Capture by Anti-Peptide Antibodies (SISCAPA), RT-PCR, or imaging technology such as immunostaining of tissue samples or in vivo immunoimaging.

### Claim 10 (depends on 1)

A method for diagnosing a condition in an individual, said method comprising the step of determining the presence of an unstable atherosclerotic plaque using the method as defined in claim 1, the presence of an unstable atherosclerotic plaque being indicative of said condition, wherein said condition is (i) a vascular or metabolic disease, or (ii) an increased predisposition to an adverse outcome.

### Claim 11 (depends on 10)

The method according to claim 10, wherein the vascular or metabolic disease is selected from the group consisting of chronic heart disease, coronary artery disease (CAD), acute coronary syndrome, unstable angina, stroke, peripheral atherosclerotic disease (PAD), aortic dissection, aneurysm, diabetes, renal insufficiency, dyslipidaemia, thrombotic disorder, metabolic syndrome, and the adverse outcome is selected from the group consisting of death, heart failure, stroke and myocardial infarction.

### Claim 12 (depends on 1)

A method for evaluating the likelihood that an individual will benefit from a treatment with an agent to reduce the risk of cardiovascular disease, comprising the step of determining the presence of an unstable atherosclerotic plaque by the method as defined in claim 1, the presence of an unstable atherosclerotic plaque being indicative of the likelihood of a benefit from the treatment.

### Claim 13 (depends on 1)

A kit for carrying out the method as claimed in claim 1, comprising means for detecting at least two biochemical markers selected from the group consisting of:
alpha B crystallin,
calponin-1,
phosphatidylethanolamine-binding protein 1,
aciculin,
mature cathepsin K,
osteoglycin,
peroxiredoxin-2,
dihydropyrimidinase-like 3,
serum amyloid P component,
serpin B9,
serpin B9-granzyme B complex,
pro-cathepsin D,
thrombospondin-2,
thrombospondin-1,
pro-collagen C-endopeptidase enhancer-1,
IL-12,
vascular endothelial growth factor,
IL-8,
IL-1ra,
granulocyte colony-stimulating factor,
growth-regulated alpha protein,
IL-13,
leukemia inhibitory factor,
IL-1 alpha,
IL-1 beta,
interferon alpha-2,
stromal cell derived factor 1 alpha,
microfibril-associated protein-4,
DJ-1 oncogene,
tissue inhibitor of metalloproteinase 1, and
heat shock protein 27.

### Claim 14

An in vitro method for identifying markers of the presence of an unstable atherosclerotic plaque in an individual, comprising the steps of:
preparing a protein extract from a biological sample representative of a stable atherosclerotic plaque,
preparing a protein extract from a biological sample representative of an unstable atherosclerotic plaque,
decreasing the proportion of the proteins which are the most abundant in the protein extracts in order to obtain depleted protein extracts enriched in scarce proteins,
separating the proteins present in the depleted protein extracts,
identifying the markers of the presence of an unstable atherosclerotic plaque,
wherein said markers are the proteins that are differently expressed in the biological sample representative of the unstable atherosclerotic plaque compared to the biological sample representative of the stable atherosclerotic plaque.

### Claim 15 (depends on 14)

The method according to claim 14, wherein the biological samples representative of stable and unstable atherosclerotic plaques are tissue samples of stable and unstable atherosclerotic plaques, respectively.

### Claim 16 (depends on 15)

The method according to claim 15, wherein the tissue samples of stable and unstable atherosclerotic plaques are taken from two distinct areas of the same atherosclerotic plaque.

### Claim 17 (depends on 15)

The method according to claim 15, wherein the tissue samples of stable and unstable atherosclerotic plaques are taken from an artery.

### Claim 18 (depends on 14)

The method according to claim 14, wherein the decrease of the proportion of the proteins which are the most abundant in the protein extract is carried out using ligands that preferentially bind to the proteins which are the most abundant in the protein extract.

### Claim 19 (depends on 18)

The method according to claim 18, wherein the ligands that preferentially bind to the proteins which are the most abundant in the protein extract are bound to a chromatographic support.

### Claim 20 (depends on 14)

The method according to claim 14, wherein the step of identifying the markers of the presence of an unstable atherosclerotic plaque is carried out by a technique selected from the group consisting of Western and dot Blot, mass spectrometry, multiple reaction monitoring, protein arrays and immunoassays.
